Log in

NASDAQ:NVIVInvivo Therapeutics Stock Price, Forecast & News

$1.44
+0.01 (+0.70 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.43
Now: $1.44
$1.46
50-Day Range
$1.43
MA: $1.60
$2.07
52-Week Range
$1.09
Now: $1.44
$25.80
Volume49,900 shs
Average Volume460,387 shs
Market Capitalization$7.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Read More
Invivo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.15 per share

Profitability

Net Income$-11,830,000.00

Miscellaneous

Employees6
Market Cap$7.03 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

How has Invivo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Invivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVIV stock has decreased by 10.0% and is now trading at $1.44. View which stocks have been most impacted by Coronavirus.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Invivo Therapeutics.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) released its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter. View Invivo Therapeutics' earnings history.

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics's stock reverse split on the morning of Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Has Invivo Therapeutics been receiving favorable news coverage?

Headlines about NVIV stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invivo Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Invivo Therapeutics.

Are investors shorting Invivo Therapeutics?

Invivo Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 202,800 shares, an increase of 36.9% from the June 15th total of 148,100 shares. Based on an average daily trading volume, of 791,700 shares, the short-interest ratio is currently 0.3 days. Approximately 4.5% of the company's stock are short sold. View Invivo Therapeutics' Current Options Chain.

Who are some of Invivo Therapeutics' key competitors?

What other stocks do shareholders of Invivo Therapeutics own?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the following people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
  • Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
  • Mr. William D'Agostino PE, Sr. VP of Operations

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.44.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $7.03 million. Invivo Therapeutics employs 6 workers across the globe.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is www.invivotherapeutics.com.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.